DengYueMed

Independent Intelligence on Global Oncology & Rare Disease Markets

Policy · Innovation · Market Access · Competitive Strategy

Focused coverage across FDA · EMA · NMPA · Global Biopharma Markets

DengYueMed is an independent pharmaceutical intelligence platform delivering insights on drug innovation, pharmaceutical markets, and global regulatory policy. The platform covers oncology, rare diseases, regulatory developments, and pharmaceutical supply chains across major global markets including the United States, Europe, and China.

Lead Analysis

CRISPR Gene Therapy Enters the Clinical Era: Casgevy Approval Marks the Dawn of Gene Editing Treatments

April 03, 2026

The approval of Casgevy, the world’s first CRISPR-based therapy, marks a historic milestone in medicine, transitioning gene editing from lab research to life-changing clinical treatment.

Read Full Analysis →

Latest Insights

CRISPR Gene Therapy Enters the Clinical Era: Casgevy Approval Marks the Dawn of Gene Editing Treatments
April 03, 2026
Latest Advances in Anti-Angiogenic Therapy (2025–2026)
April 03, 2026
China’s ADC Global Expansion: 44 Deals, $53.2B in Value, and a Shift to Technology Leadership
April 02, 2026
CAR-T 2.0 Era: Rapid Manufacturing, Dual Targeting and Reduced Toxicity in 2026
April 01, 2026
How Do PD-1/PD-L1 Inhibitors Work? Mechanisms of Cancer Immunotherapy Explained
March 31, 2026
Why β₁-Selective Beta-Blockers Remain Important in Cardiovascular Therapy
March 30, 2026

Industry Intelligence

Drug Intelligence

Market Intelligence

Policy Intelligence

Market Watch

© 2026 DengYueMed. Independent pharmaceutical intelligence platform.

This site uses Just the Docs, a documentation theme for Jekyll.